evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

113 questions · 114 findings · 6 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 36 · 31.6%GRADE not reported 3 · 2.6%Very low 16 · 14%Low 28 · 24.6%Moderate 18 · 15.8%High 13 · 11.4%

Lithium vs haloperidol

Adverse events · acute mania

The review found no eligible studies for this question.

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania

It is very uncertain whether lithium changes efficacy: response (categorical) BMRS change ≥ 50% from baseline to… compared with zuclopenthixol (very low certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 1.33 [0.3, 5.91]
    1 study · 28 participants
    Very low

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania

The review found no eligible studies for this question.

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Lithium vs placebo

Adverse event: tremor · acute mania

Lithium leads to higher adverse event: tremor compared with placebo (high certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 3.25 [2.1, 5.04]
    6 studies · 1241 participants
    High

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

Acceptability: total withdrawals · acute mania

It is very uncertain whether lithium changes acceptability: total withdrawals compared with zuclopenthixol (very low certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.78 [0.17, 3.49]
    1 study · 28 participants
    Very low

Lithium vs RISPERIDONE

Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Lithium vs RISPERIDONE

Efficacy: response (continuous) YMRS/MRS change at the end of the study · acute mania
1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    no estimate extracted
    3 studies · 241 participants
    Low

Lithium vs RISPERIDONE

Efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania by end of study · acute mania

Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12/absence of DSM‐IV mania… compared with risperidone (low certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 1.3 [0.11, 14.95]
    2 studies · 211 participants
    Low

Lithium vs RISPERIDONE

Acceptability: total withdrawals · acute mania

Lithium probably leads to higher acceptability: total withdrawals compared with risperidone (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 1.85 [1.02, 3.34]
    3 studies · 255 participants
    Moderate

Lithium vs RISPERIDONE

Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · acute mania

Lithium probably leads to lower adverse events: drowsiness/ somnolence compared with risperidone (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.43 [0.24, 0.75]
    2 studies · 219 participants
    Moderate

Lithium vs ARIPIPRAZOLE

Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania

The review found no eligible studies for this question.

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    no estimate extracted
    Studies not reported
    No studies found

Lithium vs ARIPIPRAZOLE

Efficacy: response (continuous) YMRS change by ≥ 50% at end of study · acute mania

Lithium showed no clear difference in efficacy: response (continuous) YMRS change by ≥ 50% at end of study compared with aripiprazole (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.96 [0.62, 1.51]
    1 study · 309 participants
    Moderate

Lithium vs ARIPIPRAZOLE

Remission · acute mania

Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with aripiprazole (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.99 [0.63, 1.56]
    1 study · 309 participants
    Moderate

Lithium vs placebo

Somnolence · acute mania

Lithium leads to higher adverse event: somnolence compared with placebo (high certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 2.28 [1.46, 3.58]
    7 studies · 1351 participants
    High

Lithium vs ARIPIPRAZOLE

Acceptability: total withdrawals · acute mania

Lithium showed no clear difference in acceptability: total withdrawals compared with aripiprazole (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.94 [0.6, 1.46]
    1 study · 315 participants
    Moderate

Lithium vs ARIPIPRAZOLE

Adverse event: tremor · acute mania

Lithium showed no clear difference in adverse events: tremor compared with aripiprazole (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 1.45 [0.65, 3.24]
    1 study · 313 participants
    Moderate

Lithium vs ARIPIPRAZOLE

Adverse events: somnolence/sedation · acute mania

Lithium showed no clear difference in adverse events: somnolence/sedation compared with aripiprazole (moderate certainty).

1 finding from 1 review
  • Lithium for acute mania 2019 · Cochrane Headline outcomes only
    OR 0.56 [0.26, 1.23]
    1 study · 313 participants
    Moderate

Lithium vs ARIPIPRAZOLE

Adverse events: clinically relevant (> 7%) weight gain · acute mania

Lithium showed no clear difference in adverse events: clinically relevant (> 7%) weight gain compared with aripiprazole (low certainty).

1 finding from 1 review